CRVO (CervoMed) Total Current Assets : $38.58 Mil (As of Mar. 2025)

View and export this data going back to 1996. Start your Free Trial

What is CervoMed Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. CervoMed's total current assets for the quarter that ended in Mar. 2025 was $38.58 Mil.

CervoMed Total Current Assets Historical Data

The historical data trend for CervoMed's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CervoMed Total Current Assets Chart

CervoMed Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

18.78

37.82

4.16

9.97

43.08

CervoMed Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Current Assets	Get a 7-Day Free Trial															7.97	47.33	48.81	43.08	38.58

CervoMed Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

CervoMed's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	38.922	+	2.254	+	0	+	1.906
	=	43.08

CervoMed's Total Current Assets for the quarter that ended in Mar. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	35.245	+	1.629	+	0	+	1.703
	=	38.58

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

CervoMed (NAS:CRVO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

CervoMed's Liquidation Value for the quarter that ended in Mar. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	35.245	-	3.943	+	0.75 * 0	+	0.5 * 0
=	31.30

CervoMed Total Current Assets Related Terms

Thank you for viewing the detailed overview of CervoMed's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

CervoMed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

DP8:Germany DP8:Germany

Address

20 Park Plaza, Suite 424, Boston, MA, USA, 02116

Website

https://www.cervomed.com

CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Executives

William Robert Elder	officer: GC & Secretary	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Sylvie Gregoire	director, 10 percent owner	940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner	officer: Chief Financial Officer	C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Frank Zavrl	director	C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Marwan Sabbagh	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Kelly Blackburn	officer: VP, Clinical Development	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jeffrey V. Poulton	director	300 THIRD STREET, CAMBRIDGE MA 02142
John J Alam	director, 10 percent owner, officer: CEO and President	130 WAVERLY STREET, CAMBRIDGE MA 02139
Jill Davidson	director	300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger	officer: Chief Regulatory Officer	300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois	director	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney	director	1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr.	director	C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway	officer: Chief Medical Officer	1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth	director	DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902